See more : Climb Global Solutions, Inc. (CLMB) Income Statement Analysis – Financial Results
Complete financial analysis of Ipsen S.A. (IPN.PA) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Ipsen S.A., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- Australia and New Zealand Banking Group Limited (ANEWF) Income Statement Analysis – Financial Results
- Fernhill Beverage, Inc. (FHBC) Income Statement Analysis – Financial Results
- KORE Mining Ltd. (KORE.V) Income Statement Analysis – Financial Results
- Scottie Resources Corp. (SCOT.V) Income Statement Analysis – Financial Results
- TCI Industries Limited (TCIIND.BO) Income Statement Analysis – Financial Results
Ipsen S.A. (IPN.PA)
About Ipsen S.A.
Ipsen S.A. operates as a biopharmaceutical company worldwide. The company provides drugs in the areas of oncology, neuroscience, gastroenterology, cognitive disorders, and rare diseases. It offers Somatuline for neuroendocrine tumors and acromegaly; Decapeptyl for the treatment of advanced metastatic prostate cancer; Cabometyx for renal cell and second-line hepatocellular carcinoma; Onivyde for second-line metastatic pancreatic cancer; Dysport for motor muscular disorders and medical aesthetics; NutropinAq for growth failure in children due to growth hormone (GH) deficiency, turner syndrome, chronic renal failure, and GH deficiency in adults; and Increlex for growth failure in children and adolescents. The company also offers Smecta for chronic and acute diarrhea, and pain associated with functional bowel diseases; Forlax for constipation; Fortrans/Eziclen for bowel cleansing prior to endoscopy, X-ray examination, and colonic surgery; and Tanakan for cognitive disorders in adults, vertigo of vestibular origin and vestibular rehabilitation, and tinnitus. In addition, it provides Xermelo for the carcinoid syndrome; Cometriq for medullary thyroid cancer; Smebiocta/SmectaFlora Protect, a food supplement; SmectaGas, a medical device used in the symptomatic treatment of gas-related gastrointestinal disorders and relief of gas-related symptoms; and Etiasa for inflammatory bowel diseases. Further, the company offers other consumer healthcare products in the gastro-intestinal area, including Buscopan, Clin4000, Prontalgine, Suppositoria Glycerini, Mucothiol, Floractin, and Mucodyne. Ipsen S.A. has agreements with Debiopharm; Exelixis; Galderma; Blueprint Medicines; TerSera Therapeutics; Rhythm Pharmaceuticals; Teijin; Braintree Laboratories; Ethypharm; Schwabe; BAKX Therapeutics Inc.; and Exicure. The company was founded in 1929 and is headquartered in Boulogne-Billancourt, France.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 3.31B | 3.16B | 2.75B | 2.69B | 2.69B | 2.35B | 2.01B | 1.67B | 1.52B | 1.33B | 1.28B | 1.28B | 1.23B | 1.17B | 1.11B | 1.04B | 993.76M | 861.68M | 788.71M | 723.99M |
| Cost of Revenue | 571.20M | 527.70M | 438.60M | 490.60M | 488.00M | 454.20M | 385.60M | 351.10M | 336.80M | 310.00M | 305.30M | 254.77M | 249.24M | 236.19M | 237.81M | 219.93M | 199.03M | 181.38M | 176.83M | 176.31M |
| Gross Profit | 2.74B | 2.63B | 2.31B | 2.20B | 2.20B | 1.89B | 1.63B | 1.32B | 1.18B | 1.02B | 976.50M | 1.02B | 985.67M | 934.11M | 874.58M | 818.18M | 794.73M | 680.30M | 611.88M | 547.68M |
| Gross Profit Ratio | 82.72% | 83.28% | 84.04% | 81.74% | 81.88% | 80.66% | 80.83% | 78.99% | 77.85% | 76.73% | 76.18% | 80.06% | 79.82% | 79.82% | 78.62% | 78.81% | 79.97% | 78.95% | 77.58% | 75.65% |
| Research & Development | 619.30M | 445.30M | 424.40M | 405.60M | 388.80M | 302.10M | 265.80M | 231.30M | 192.60M | 186.90M | 215.50M | 248.55M | 253.59M | 221.13M | 197.29M | 182.92M | 184.74M | 178.35M | 167.57M | 140.79M |
| General & Administrative | 217.80M | 205.80M | 188.20M | 187.80M | 181.40M | 165.70M | 140.80M | 125.60M | 122.90M | 111.20M | 103.80M | 99.09M | 101.47M | 98.25M | 88.46M | 85.90M | 80.43M | -232.58M | -225.80M | -318.06M |
| Selling & Marketing | 917.10M | 833.40M | 728.10M | 784.00M | 838.60M | 787.40M | 715.90M | 592.00M | 541.40M | 464.10M | 442.90M | 473.48M | 425.15M | 422.81M | 396.14M | 358.40M | 321.05M | 307.80M | 292.59M | 319.24M |
| SG&A | 1.13B | 1.04B | 916.20M | 972.20M | 1.02B | 954.10M | 857.60M | 718.80M | 665.90M | 577.10M | 548.50M | 572.57M | 526.62M | 521.06M | 484.61M | 444.30M | 401.48M | 75.22M | 66.79M | 1.18M |
| Other Expenses | 165.00M | 17.70M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -21.70M | -7.20M | -9.20M | -6.26M | -20.21M | 7.92M | 12.76M | -3.47M | -677.00K | 17.41M | -12.62M | -2.62M | -1.58M |
| Operating Expenses | 1.92B | 1.91B | 1.50B | 1.64B | 2.21B | 1.39B | 1.25B | 1.02B | 942.50M | 812.90M | 781.20M | 847.08M | 788.13M | 705.15M | 702.11M | 635.48M | 585.85M | 485.82M | 450.71M | 411.01M |
| Cost & Expenses | 2.49B | 2.43B | 1.94B | 2.13B | 2.70B | 1.85B | 1.63B | 1.37B | 1.28B | 1.12B | 1.09B | 1.10B | 1.04B | 941.35M | 939.91M | 855.41M | 784.88M | 667.19M | 627.55M | 587.32M |
| Interest Income | 0.00 | 5.30M | 1.90M | 2.30M | 2.00M | 5.20M | 8.10M | 3.70M | 800.00K | 1.20M | 6.20M | 1.67M | 244.00K | 2.24M | 2.70M | 21.43M | 11.54M | 1.19M | -204.00K | -475.00K |
| Interest Expense | 19.40M | 23.80M | 23.70M | 27.10M | 30.00M | 8.40M | 9.20M | 4.60M | 1.20M | 5.90M | 4.82M | 5.37M | 1.76M | 1.59M | 4.40M | 4.35M | 13.49M | 2.48M | 6.53M | 10.59M |
| Depreciation & Amortization | 282.00M | 201.30M | 246.40M | 234.70M | 161.20M | 142.60M | 97.90M | 49.10M | 38.00M | 33.70M | 25.60M | 72.56M | 114.69M | 39.39M | 44.94M | 50.65M | 41.23M | 49.94M | 28.87M | 35.02M |
| EBITDA | 1.14B | 1.13B | 1.06B | 794.40M | 152.70M | 645.00M | 486.90M | 387.00M | 351.60M | 283.20M | 251.80M | 198.19M | 148.00M | 166.37M | 216.64M | 246.78M | 249.05M | 237.76M | 190.41M | 150.67M |
| EBITDA Ratio | 34.57% | 35.83% | 38.54% | 34.61% | 32.07% | 28.45% | 24.20% | 23.16% | 23.13% | 21.25% | 19.64% | 19.30% | 22.64% | 22.77% | 19.48% | 23.00% | 26.32% | 28.79% | 24.07% | 22.30% |
| Operating Income | 816.00M | 943.70M | 886.20M | 759.00M | 701.80M | 555.30M | 400.40M | 348.20M | 313.60M | 249.50M | 226.20M | 114.80M | 75.78M | 128.80M | 172.47M | 180.09M | 208.89M | 187.22M | 161.69M | 125.92M |
| Operating Income Ratio | 24.68% | 29.90% | 32.24% | 28.26% | 26.06% | 23.65% | 19.90% | 20.84% | 20.63% | 18.73% | 17.65% | 8.99% | 6.14% | 11.01% | 15.50% | 17.35% | 21.02% | 21.73% | 20.50% | 17.39% |
| Total Other Income/Expenses | -59.90M | -25.50M | -35.20M | 6.30M | -1.40M | -24.20M | -25.20M | -4.80M | -3.90M | -13.10M | -9.00M | -8.27M | -71.22M | -16.17M | -5.16M | 1.98M | -2.03M | -1.54M | -6.68M | -10.28M |
| Income Before Tax | 756.10M | 704.40M | 789.50M | 531.10M | -34.80M | 495.20M | 372.00M | 299.90M | 240.10M | 208.30M | 201.50M | 120.26M | 41.37M | 125.40M | 167.31M | 181.16M | 206.86M | 185.68M | 155.01M | 115.64M |
| Income Before Tax Ratio | 22.87% | 22.32% | 28.72% | 19.77% | -1.29% | 21.09% | 18.49% | 17.95% | 15.79% | 15.63% | 15.72% | 9.41% | 3.35% | 10.71% | 15.04% | 17.45% | 20.82% | 21.55% | 19.65% | 15.97% |
| Income Tax Expense | 136.20M | 112.30M | 158.30M | 17.80M | 19.60M | 108.10M | 101.40M | 73.50M | 49.80M | 53.80M | 59.30M | 24.44M | -13.34M | 16.96M | 10.59M | 33.32M | 54.48M | 40.89M | 32.64M | 40.24M |
| Net Income | 644.40M | 648.60M | 646.60M | 548.00M | -54.90M | 389.50M | 272.30M | 225.90M | 189.90M | 153.50M | 152.54M | -29.49M | 424.00K | 95.68M | 157.17M | 147.67M | 151.07M | 144.01M | 119.23M | 83.00M |
| Net Income Ratio | 19.49% | 20.55% | 23.52% | 20.40% | -2.04% | 16.59% | 13.54% | 13.52% | 12.49% | 11.52% | 11.90% | -2.31% | 0.03% | 8.18% | 14.13% | 14.22% | 15.20% | 16.71% | 15.12% | 11.46% |
| EPS | 7.79 | 7.20 | 7.64 | 6.61 | -0.66 | 4.67 | 3.27 | 2.74 | 2.30 | 1.88 | 1.71 | -0.35 | 0.01 | 1.13 | 1.86 | 1.75 | 1.80 | 1.71 | 1.42 | 0.99 |
| EPS Diluted | 7.73 | 7.14 | 7.57 | 6.57 | -0.66 | 4.68 | 3.25 | 2.73 | 2.29 | 1.87 | 1.70 | -0.35 | 0.01 | 1.13 | 1.86 | 1.74 | 1.79 | 1.71 | 1.42 | 0.99 |
| Weighted Avg Shares Out | 82.72M | 83.08M | 83.37M | 83.41M | 83.10M | 83.33M | 83.08M | 82.71M | 82.71M | 82.35M | 83.29M | 83.16M | 83.22M | 84.51M | 84.30M | 83.93M | 83.88M | 84.21M | 84.02M | 84.02M |
| Weighted Avg Shares Out (Dil) | 83.38M | 83.10M | 83.36M | 83.45M | 83.51M | 83.25M | 83.03M | 82.62M | 82.70M | 82.22M | 83.16M | 83.46M | 83.47M | 84.51M | 84.30M | 84.02M | 83.97M | 84.21M | 84.02M | 84.02M |
Source: https://incomestatements.info
Category: Stock Reports